Tilray Inc (NASDAQ:TLRY) – Equities researchers at Seaport Global Securities upped their Q2 2019 EPS estimates for Tilray in a report issued on Tuesday, May 28th, according to Zacks Investment Research. Seaport Global Securities analyst B. Hundley now anticipates that the company will post earnings per share of ($0.22) for the quarter, up from their prior estimate of ($0.23). Seaport Global Securities has a “Neutral” rating and a $81.10 price target on the stock. Seaport Global Securities also issued estimates for Tilray’s Q3 2019 earnings at ($0.22) EPS, Q4 2019 earnings at ($0.17) EPS, FY2019 earnings at ($0.88) EPS, Q1 2020 earnings at ($0.16) EPS, Q2 2020 earnings at ($0.14) EPS, Q3 2020 earnings at ($0.07) EPS and FY2020 earnings at ($0.38) EPS.
Other analysts have also issued reports about the stock. Vertical Research began coverage on shares of Tilray in a research note on Friday, April 12th. They issued a “sell” rating for the company. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Tilray in a research note on Tuesday, April 2nd. Compass Point began coverage on shares of Tilray in a report on Monday, June 10th. They issued a “neutral” rating and a $41.00 target price on the stock. Roth Capital reiterated a “hold” rating on shares of Tilray in a report on Thursday, March 21st. Finally, Zacks Investment Research upgraded shares of Tilray from a “sell” rating to a “hold” rating in a report on Tuesday, May 21st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $79.57.
Shares of NASDAQ:TLRY traded down $1.69 during trading on Thursday, reaching $39.01. The company had a trading volume of 1,368,107 shares, compared to its average volume of 1,637,399. The firm has a market cap of $3.96 billion and a P/E ratio of -47.57. Tilray has a twelve month low of $20.10 and a twelve month high of $300.00. The company has a current ratio of 2.35, a quick ratio of 2.06 and a debt-to-equity ratio of 1.13.
Tilray (NASDAQ:TLRY) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The company had revenue of $23.00 million during the quarter, compared to analyst estimates of $20.50 million. Tilray had a negative return on equity of 43.71% and a negative net margin of 159.09%. The firm’s quarterly revenue was up 194.9% on a year-over-year basis.
In other Tilray news, CRO Edward Wood Pastorius, Jr. sold 3,443 shares of the company’s stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $61.04, for a total value of $210,160.72. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Mark Castaneda sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $51.72, for a total transaction of $517,200.00. The disclosure for this sale can be found here. Insiders sold a total of 166,109 shares of company stock worth $10,409,698 over the last quarter. Insiders own 3.40% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Lee Financial Co acquired a new stake in shares of Tilray during the 1st quarter worth about $25,000. Quantamental Technologies LLC bought a new position in shares of Tilray in the 1st quarter valued at about $26,000. Toronto Dominion Bank bought a new position in shares of Tilray in the 4th quarter valued at about $27,000. PNC Financial Services Group Inc. boosted its stake in shares of Tilray by 105.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 463 shares of the company’s stock valued at $30,000 after purchasing an additional 238 shares during the last quarter. Finally, Kore Private Wealth LLC bought a new position in shares of Tilray in the 1st quarter valued at about $41,000. 2.04% of the stock is owned by hedge funds and other institutional investors.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.